Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies

James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
European Respiratory Journal 2020 56: 2000110; DOI: 10.1183/13993003.00110-2020
James D. Chalmers
1University of Dundee, Dundee, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jchalmers@dundee.ac.uk
David Cipolla
2Insmed Incorporated, Bridgewater, NJ, USA
3Aradigm Corporation, Hayward, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Thompson
4Theta Hat Statistical Consultants LLC, Owings Mills, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela M. Davis
5Grifols, Research Triangle Park, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne O'Donnell
6Georgetown University, Washington, DC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Tino
7University of Pennsylvania, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Igor Gonda
3Aradigm Corporation, Hayward, CA, USA
8Respidex LLC, Dennis, MA 02638, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Haworth
9Royal Papworth Hospital and Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juergen Froehlich
3Aradigm Corporation, Hayward, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

It is not known if inhaled antibiotics improve respiratory symptoms in patients with bronchiectasis. In the recent phase-3 ORBIT trials, 48 weeks' treatment with ARD-3150 (inhaled liposomal ciprofloxacin) did not significantly improve symptoms using the prespecified method of analysis comparing baseline symptoms to those after 48 weeks, when patients had been off treatment for 28 days. This method of analysis does not take account of possible improvements in symptoms while on active treatment.

A post hoc analysis of two identical randomised trials of ARD-3150 (ORBIT-3 and -4) administered 28 days on and 28 days off in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. The quality-of-life bronchiectasis respiratory symptom scale (QOL-B-RSS), which has a one-week recall period, was administered every 28 days. We examined whether respiratory symptoms improved during on-treatment periods and the relationship of changes in QOL-B-RSS to changes in bacterial load using a mixed-model repeated measures approach.

ARD-3150 treatment resulted in a significant improvement in respiratory symptoms during the on-treatment periods with concordant results between ORBIT-3 (estimate 1.4 points, se 0.49; p=0.004) and ORBIT-4 (estimate 1.1 point, se 0.41; p=0.006). The proportion of patients achieving a symptom improvement above the minimum clinically important difference was higher with ARD-3150 compared with placebo during on-treatment cycles (p=0.024). Changes in respiratory symptoms were correlated with changes in bacterial load in the treatment group (r=−0.89, p<0.0001). Individual estimates for decrements in the QOL-B RSS during exacerbation were −9.4 points (se 0.91) in ORBIT-3 and −10.8 points (0.74) in ORBIT-4 (both p<0.0001).

Inhaled ARD-3150 resulted in significant improvements in respiratory symptoms during the on-treatment periods which were lost during off-treatment periods. These results supports the concept that reducing bacterial load can improve respiratory symptoms in patients with bronchiectasis.

Abstract

Inhaled ciprofloxacin improves symptoms in patients with bronchiectasis https://bit.ly/2ZzvQdv

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • This study is registered as a clinical trial, identifier NCT01515007 and NCT02104245. Data are available from Aradigm Corporation.

  • Conflict of interest: J.D. Chalmers reports grants and personal fees from AstraZeneca, GlaxoSmithKline, Grifols, Insmed and Boehringer Ingelheim, personal fees from Chiesi, grants from Gilead, outside the submitted work.

  • Conflict of interest: D. Cipolla has patents US 10,420,765, US 9,987,227, US 9,968,555, US 9,844,548, US 9,545,401, US 9,259,424, US 9,078,897, US 9,028,864, US 8,414,915, US 8,268,347, US 8,119,156, and US 8,071,127 issued.

  • Conflict of interest: B. Thompson reports personal fees for consultancy from Aradigm, during the conduct of the study.

  • Conflict of interest: A.M. Davis is an employee of Grifols.

  • Conflict of interest: A. O'Donnell reports personal fees from Aradigm, during the conduct of the study.

  • Conflict of interest: G. Tino has nothing to disclose.

  • Conflict of interest: I. Gonda reports personal fees from Aradigm Corporation, during the conduct of the study; hold shares in Aradigm Corporation, outside the submitted work; and has two patents licensed with Aradigm Corporation.

  • Conflict of interest: C. Haworth reports personal fees for research from Aradigm, personal fees for consultancy and lectures from Grifols, during the conduct of the study; personal fees for consultancy and lectures from Zambon/Profile, personal fees for consultancy from Chiesi, Gilead and GSK, grants and personal fees for consultancy and lectures from Insmed, grants from Novartis, grants and personal fees for lectures from TEVA, outside the submitted work.

  • Conflict of interest: J. Froehlich is an employee of Aradigm.

  • Support statement: The study was funded by Aradigm Corporation. J.D. Chalmers is supported by the British Lung Foundation Chair of Respiratory Research and a Scottish Senior Fellowship from the Chief Scientist Office. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received January 18, 2020.
  • Accepted May 21, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 4 Table of Contents
European Respiratory Journal: 56 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
European Respiratory Journal Oct 2020, 56 (4) 2000110; DOI: 10.1183/13993003.00110-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
European Respiratory Journal Oct 2020, 56 (4) 2000110; DOI: 10.1183/13993003.00110-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • EmPHasis-10 as a measure of quality of life in PAH
  • EmPHasis-10 health-related quality of life score predicts outcomes in PAH
  • Periostin and airway epithelial function in asthma
Show more Original Articles

Bronchiectasis

  • Efficacy and safety of TOBI Podhaler in P. aeruginosa-infected bronchiectasis
  • Sputum neutrophil elastase, microbiota and P. aeruginosa in bronchiectasis
Show more Bronchiectasis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society